A carregar...
Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes
BACKGROUND: EDC1 is a novel type of antibody-drug conjugate which binds and inhibits the Na,K-ATPase on the surface of cancer cells expressing dysadherin. The purpose of this study was to determine the expression of dysadherin in different types of thyroid carcinoma, and evaluate the therapeutic pot...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5421862/ https://ncbi.nlm.nih.gov/pubmed/28160550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14904 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|